Quick Answer
Maze Therapeutics, Inc. reported Net Income of -$131.12 million for fiscal year 2025.
Maze Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$131.12M | -351.0% |
| 2024 | $52.23M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$30.09M | -21.6% | +10.7% |
| June 30, 2025 | -$33.68M | -124.2% | -2.7% |
| March 31, 2025 | -$32.79M | -0.9% | -32.5% |
| September 30, 2024 | -$24.75M | — | -117.8% |
| June 30, 2024 | $139.06M | — | +527.9% |
| March 31, 2024 | -$32.49M | — | — |
- Maze Therapeutics, Inc. showed a decrease of -351.0% in Net Income compared to the prior fiscal year.
- Over the 2024–2025 period, Maze Therapeutics, Inc.’s net income has declined by 351.0% (from $52.23 million to -$131.12 million).
- The most recent figure is from Maze Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: